Biovail was a major international pharmaceutical company with reported revenues of $ 788 million. Banc of America released a study report which indicated that the Biovail Corporation Financial Statements "raised a number of issues that require caution for investors", and as a result, shares of Biovail was given to "sell" rating Banc of America. Member of the Audit Committee Biovail is training for the upcoming meeting of audit and considers the consequences of this report for the company and to the audit committee. "Hide
by Mary Heisz, Mary Jane Mastrandea, Jessica Frisch Source: Richard Ivey School of Business Foundation 19 pages. Publication Date: 07 January 2009. Prod. #: 909B04-PDF-ENG
Related Case Solutions & Analyses:
Interview with Edward Stroz and Eric Friedberg Co-Presidents of Stroz Friedberg
CRP Products
Arthur Andersen (C): The Collapse of Arthur Andersen
Note on Accounting for Contingencies
IFRS: Canadas Decision
Positioning the Tata Nano (B)
Ujaala Borderline General Insurance Company Limited
Key State Blue Cross and Blue Shield Plan: Strategy for Winning in the Market through Customer-Focused Service
Financial Reporting Tax Reporting and the Role of Deferred Taxes
Emergence of an International Accounting Standards Setter
